EMMA Emmaus Life Sciences Inc

Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies including those in the rare and orphan disease categories. For more information, please visit www.emmausmedical.com.

Company profile

Ticker

EMMA

Exchange

NASDAQ

Website

www.emmausmedical.com

CEO

Yutaka Niihara

Incorporated in

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Health Technology > Other Health Care

Industry (SEC)

Pharmaceutical Preparations

Pfizer • Merck & Co. • Allergan • Johnson & Johnson • Abbott Laboratories • Teva Pharmaceutical Industries • Bristol Myers Squibb • ELI LILLY & Co • Warner Chilcott • AbbVie ...

Former names

Age Research Inc, CNS Response, Inc., MYnd Analytics, Inc., SalesTactix, Inc., Strativation, Inc.

SEC CIK

0000822370

Corporate docs

Articles of Incorporation & Bylaws

IRS number

870419387

EMMA stock data

S&P 500

1M 1Y 2Y 5Y

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

13 Nov 19

3 Jun 20

31 Dec 20

News

Company financial data Financial data

Chart EMMA financial data

Quarter (USD)	Sep 19	Jun 19	Mar 19	Dec 18
Revenue	6.08M	527K	460.1K	387.1K
Net income	-26.14M	-2.12M	-2.26M	-2.38M
Diluted EPS	-0.6	-0.2	-0.27	-0.32
Net profit margin	-430%	-403%	-491%	-614%
Operating income	-3.6M	-2.7M	-2.68M	-2.68M
Net change in cash	11.1M	1.24M	-15.88M	13.83M
Cash on hand	13.55M	2.44M	1.2M	17.08M
Cost of revenue	178K	407.6K	296.3K	225.1K

Financial data from company earnings reports

Recent insider trades

EMMA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	$Price	#Shares	$Value	#Remaining
1 Jun 20	Niihara Yutaka	Common stock, $0.001 par value	Buy	Aquire P	1.6	2,500	4K	10,645,493
29 May 20	Niihara Yutaka	Common stock, $0.001 par value	Buy	Aquire P	1.51	3,200	4.83K	10,642,993
28 May 20	Niihara Yutaka	Common stock, $0.001 par value	Buy	Aquire P	1.37	2,200	3.01K	10,639,793
27 May 20	Niihara Yutaka	Common stock, $0.001 par value	Buy	Aquire P	1.35	500	675	10,637,593
26 May 20	Niihara Yutaka	Common stock, $0.001 par value	Buy	Aquire P	1.37	600	822	10,637,093
22 May 20	Niihara Yutaka	Common stock, $0.001 par value	Buy	Aquire P	1.38	1,000	1.38K	10,636,493
21 May 20	Niihara Yutaka	Common stock, $0.001 par value	Buy	Aquire P	1.37	1,700	2.33K	10,635,493
20 May 20	Niihara Yutaka	Common stock, $0.001 par value	Buy	Aquire P	1.4	4,000	5.6K	10,633,793
18 May 20	Niihara Yutaka	Common stock, $0.001 par value	Buy	Aquire P	1.35	500	675	10,629,793

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2019

EMMA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	1	1	–
Opened positions	0	0	NaN%
Closed positions	0	13	-100.0%
Increased positions	0	0	NaN%
Reduced positions	0	0	NaN%

13F shares	Current	Prev Q	Change
Total value	0	0	–
Total shares	0	0	–
Total puts	0	0	–
Total calls	0	0	–
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Proequities	0	$0

Largest transactions	Shares	Bought/sold	Change
Proequities	0	0

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Google • TelaDoc

Management Discussion

Revenues, Net. Net revenues increased by $1.2 million, or 25%, to $6.1 million for the three months ended September 30, 2019 from $4.9 million for the three months ended September 30, 2018. Substantially all of these revenues were from sales of Endari®, and revenues from sales of AminoPure were immaterial. The increase in net revenues is primarily attributable to the higher market acceptance of Endari® and expansion of our customer base. We expect Endari® revenues to continue to increase as we expand our commercialization efforts in the United States and abroad.
Cost of Goods Sold. Cost of goods sold were $0.2 million and $0.1 million for the three months ended September 30, 2019 and the three months ended September 30, 2018, respectively. Cost of goods sold includes costs for raw material, packaging, testing, shipping and costs related to scrapped inventory. Substantially all of the raw material purchased during the three months ended September 30, 2019 and 2018 was from one vendor.
Research and Development Expenses. Research and development expenses increased by $0.3 million, or 56%, to $0.7 million for the three months ended September 30, 2019 from $0.5 million for the three months ended September 30, 2018. This increase was primarily due to an increase in expenses related to our sponsored diverticulosis study. We expect our research and development costs to increase in the remainder of 2019 as the study progresses.

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abroad, academic, adult, age, aka, America, AminoPure, anniversary, API, area, assist, Automated, bear, billion, binomial, Binominal, bore, Boulevard, branding, broker, bulk, burn, called, category, cautionary, cell, CellSeed, certainty, certification, Chargeback, Checklist, Cliquet, CMA, collaboration, communicated, comprehensive, corneal, CPA, creditor, CRO, Cultured, customary, cycle, DCP, default, defect, degree, discovery, dispensing, duty, earlier, EC, eighty, EJ, ELSK, EM, EMJ, enrollment, Epithelial, equivalent, escalation, Europe, Evercore, exclusivity, expended, expertise, exposure, extinguishment, feature, fifteen, firm, footnote, force, forecast, forty, gap, gave, GPB, Hawthorne, headquarter, Hope, Hospice, hundred, inadequate, incorrect, inducement, Inflation, inflow, infrastructure, institutional, insufficient, integral, intrinsic, introduce, inventory, investigate, issuable, Japan, Japanese, JPY, kilogram, Korea, Korean, KOSDAQ, KPM, KPS, KRW, lattice, launch, leasehold, lessor, loan, located, lower, mandatory, manufacturing, MCAA, Mitsubishi, mix, Mucosal, Newfield, Niihara, nominal, Nutrition, nutritional, older, orderly, partnership, past, patient, pediatric, PGLG, pharmaceutical, pharmacy, Phase, pilot, pipeline, pledged, powder, precision, preclinical, premium, prepayment, prescription, Preview, promotion, prompt, prove, ratchet, raw, reclassified, redeem, refinance, reinforce, remeasured, rental, repaid, repay, repayment, repurchase, resell, resolved, revised, RF, SCD, scrapped, segregation, sentence, shell, shipping, shorter, sickle, site, solicitation, South, specialty, sponsored, Strativation, Subtopic, Suite, summarized, superseded, supplement, supplemental, supplemented, Tech, Telcon, telephone, tenant, Tokyo, Torrance, track, traditional, UFJ, unconverted, understanding, uneven, unpredictable, unrealized, unrelated, unsecured, USD, vendor, visit, waived, website, widely, Winston, York, Zen

Removed: accessed, accretion, accurate, achieve, achieved, acquiree, activity, added, adequate, adequately, administered, advisory, affecting, affiliated, afforded, allocation, amortized, amortizing, analytical, analyzed, annually, anxiety, appeal, applied, apply, applying, approach, approximate, Arcadian, arise, arithmetic, arrangement, artificial, Aspire, assessed, assigned, assume, assumption, attended, attract, attribute, attributed, attribution, audit, authorized, award, awarded, balloon, basic, begin, behavioral, belief, Ben, beneficially, BFTP, bill, billed, billing, bipolar, Blue, book, calculated, cancellation, cancelled, Cap, capitalization, Carpenter, carryforward, clarify, classification, clause, clearance, client, climate, clinically, closed, cloud, CMS, Code, collect, collectability, collected, collection, combined, commercial, commercializing, competition, competitive, compliant, complimentary, comply, component, comprised, compute, computed, computer, concurrently, condensed, conducting, conference, conformity, consecutive, considerable, consistent, constitute, constituting, consumed, consummated, contemplate, contingent, controlling, correlation, corroborated, Cota, coupon, cover, credentialed, database, dba, DCA, deducted, deduction, delist, deliver, delivered, depending, depreciated, depression, derived, determination, develop, dilution, directed, directing, disclose, disclosing, discretion, disorder, disposition, distinct, distributed, diversity, dividing, domestic, doubtful, drawn, earned, economy, educating, EEG, efficacy, eligible, eliminate, elimination, employment, enable, enacted, enactment, encountered, enforceable, enhanced, entering, enterprise, entitled, environment, estimating, estimation, evergreen, evidence, examination, exceed, executed, execution, exempt, existence, existing, expedient, Expenditure, experienced, explore, expressed, expressly, failure, faith, family, feasibility, federally, FFS, final, finite, fix, flat, Florida, foregoing, franchise, Franklin, frequently, funded, furniture, gathering, George, good, goodwill, governing, grantor, greater, grow, growth, guarantee, heading, heavily, hedging, hierarchy, highest, history, Hooper, Horizon, hosting, identifiable, identification, identified, implementation, Important, improve, inability, inception, indirectly, individually, industry, inference, inform, inherent, initially, input, instrument, insured, intangible, intellectual, intelligence, invoice, involving, ISO, Jersey, Jill, John, judgment, jurisdiction, key, labor, laboratory, law, learning, leaving, legally, legislation, licensed, lieu, limit, Linea, liquid, liquidated, liquidity, litigation, long, lowest, machine, maintain, maintained, maintenance, manage, managed, marginal, marketplace, Mary, materiality, maximize, maximum, measuring, media, medicine, member, mentioned, methodology, Michal, Military, minimize, modifying, multiple, nasdaq, nationwide, necessitating, network, neurometric, noncontrolling, nonemployee, notice, NSO, objective, obtain, occupancy, occurring, offered, offshore, Online, open, operational, opinion, optional, order, ordered, origination, overallotment, owed, ownership, PA, package, Pappajohn, participated, participating, patented, pattern, PC, peer, Pennsylvania, percent, performed, periodically, permanent, permanently, pertaining, Peter, philanthropic, plain, platform, policy, portal, portfolio, potential, practicable, practical, practice, preceding, preferred, preliminary, prescribed, presently, President, priority, processing, production, profitability, projected, projection, promise, promulgated, prospective, Psychiatric, PTSD, purport, purpose, put, qEEG, qualification, Quantitative, ready, realization, realized, receivable, recently, record, recording, recoverability, recoverable, recovered, recruit, recruitment, redesigned, reducing, refusal, regional, register, registering, registrable, Registry, regular, regulator, reimbursement, relation, relationship, relevant, rely, rendered, renewed, repatriated, repealing, replace, replaced, reportable, representation, representative, represented, requirement, requisite, reserved, responsible, restatement, retain, reviewed, reviewing, Robin, Salesforce, satisfied, satisfy, scalable, scheduled, scheduling, science, SeeNote, segment, service, settled, settlement, Shield, short, simplified, single, sixty, small, Smith, social, software, Southeastern, speak, specific, spouse, stand, statute, statutory, stockholder, stream, strength, submitted, subordinated, subscription, successfully, suggested, sustained, symbol, tangible, taxable, taxation, technological, telebehavioral, telehealth, telepsychiatry, temporarily, temporary, tense, terminate, termination, tested, thereunder, ticker, top, traded, trademark, tradename, Treasury, twelve, type, typically, unadjusted, unanticipated, Unanue, uncertain, unchanged, underwritten, undue, unobservable, Unpaid, unsatisfied, updated, upgrade, user, utilized, vacation, validated, valuation, vanilla, vesting, veteran, videoconferencing, view, violation, Virginia, volatility, volume, voted, voting, Votruba, web, written, Yield

From filing 10-Q 2019 Q3